Australia markets closed

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
267.04+8.23 (+3.18%)
At close: 04:00PM EDT
267.49 +0.45 (+0.17%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close258.81
Open258.54
Bid266.07 x 200
Ask268.19 x 200
Day's range254.87 - 268.22
52-week range119.76 - 322.67
Volume435,650
Avg. volume568,668
Market cap5.508B
Beta (5Y monthly)-0.48
PE ratio (TTM)N/A
EPS (TTM)-20.00
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est394.54
  • GlobeNewswire

    Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

    CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warra

  • GlobeNewswire

    Madrigal Pharmaceuticals Announces Proposed Public Offering

    CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold

  • Investor's Business Daily

    Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

    Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 63 to 83.